Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Urinary Bladder Neoplasms 1Squamous Intraepithelial Lesions 1Skin Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Mycosis Fungoides 1Melanoma 1Leukoplakia 1Leukokeratosis, Hereditary Mucosal 1HIV Infections 1Glioma 1Glioblastoma 1Ependymoma 1Colorectal Neoplasms 1Carcinoma, Basal Cell 1

Interventions

Magnetic Resonance Spectroscopy 9Cyclophosphamide 7X-Rays 6Temozolomide 6Specimen Handling 6Phantoms, Imaging 6Biopsy 6Nuclear Medicine Department, Hospital 5Etoposide 5Nivolumab 4Bevacizumab 4Radiation 3Irinotecan 3Automobiles 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2lutetium Lu 177 dotatate 2larotrectinib 2ivosidenib 2etoposide phosphate 2erdafitinib 2ensartinib 2abemaciclib 2Watchful Waiting 2Radiotherapy 2ONC206 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ependymoma × Imiquimod × 1 year × Clear all
NCT01795313 2026-02-05

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

University of Pittsburgh

Phase 1 Terminated
23 enrolled

Ependymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡